A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177–labeled prostate-specific membrane antigen–targeted radioligand therapy in …
Context Castration-resistant prostate cancer (CRPC) treatment is an evolving challenge.
Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy …
Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy …
[HTML][HTML] Radiomics for identification and prediction in metastatic prostate cancer: a review of studies
Metastatic Prostate Cancer (mPCa) is associated with a poor patient prognosis. mPCa
spreads throughout the body, often to bones, with spatial and temporal variations that make …
spreads throughout the body, often to bones, with spatial and temporal variations that make …
PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
AL Giraudet, D Kryza, M Hofman… - Therapeutic …, 2021 - journals.sagepub.com
Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most
prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this …
prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this …
[HTML][HTML] Estimating the potential of radiomics features and radiomics signature from pretherapeutic PSMA-PET-CT scans and clinical data for prediction of overall …
S Moazemi, A Erle, S Lütje, FC Gaertner, M Essler… - Diagnostics, 2021 - mdpi.com
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed
tomography (PSMA-PET/CT) scans can facilitate diagnosis and treatment of prostate …
tomography (PSMA-PET/CT) scans can facilitate diagnosis and treatment of prostate …
[HTML][HTML] Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate …
R Manafi-Farid, S Harsini, B Saidi… - European Journal of …, 2021 - Springer
Background Prostate cancer (PC) is one of the most common cancers in men. Although the
overall prognosis is favorable, the management of metastatic castration-resistant prostate …
overall prognosis is favorable, the management of metastatic castration-resistant prostate …
[HTML][HTML] PSMA theranostics: science and practice
Simple Summary A significant number of prostate cancer patients will progress to metastatic
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …
[HTML][HTML] Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters
S Moazemi, A Erle, Z Khurshid, S Lütje… - Annals of …, 2021 - ncbi.nlm.nih.gov
Background Treatment with radiolabeled ligands to prostate-specific membrane antigen
(PSMA) is gaining importance in the treatment of patients with advanced prostate carcinoma …
(PSMA) is gaining importance in the treatment of patients with advanced prostate carcinoma …
[HTML][HTML] Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis
W Roll, P Schindler, M Masthoff, R Seifert, K Schlack… - Cancers, 2021 - mdpi.com
Simple Summary PSMA Therapy has recently become an additional therapeutic option in
advanced prostate cancer. In the present study, the predictive and prognostic value of …
advanced prostate cancer. In the present study, the predictive and prognostic value of …
[HTML][HTML] Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration …
S Rasul, M Hartenbach, T Wollenweber… - European journal of …, 2021 - Springer
Abstract Background and aims [177 Lu] Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a
new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand …
F Khreish, N Kochems, F Rosar, A Sabet… - European journal of …, 2021 - Springer
Purpose Little is known about the efficacy of prostate-specific membrane antigen (PSMA)–
targeted radioligand therapy (RLT) against liver metastases of metastatic castration-resistant …
targeted radioligand therapy (RLT) against liver metastases of metastatic castration-resistant …